Rheumatoid Arthritis

Blood test

Quantification of GADD34 Expression in RA

Quantification of GADD34 Expression in Rheumatoid Arthritis

GADD34 gene expression level is quantified in the PBMC by quantitative PCR.

GADD34 transcrit amplification in a sample from a healthy donor and a sample from a patient was measured 25 times in the same experiment in order to assess repeatability and in triplicate in each qPCR experiment (at least 7) in order to assess reproducibility.

GADD34 gene expression level was quantified in the PBMC of the three groups of patients and compared between the three groups.

In patients treated with therapeutical arthrocentesis, to compare GADD34 gene expression level in synovial cells compared with its level in PBMC.

Quantification of Th1 and Th2 cytokines in RA patients serum by luminex technology.

University Hospital, Grenoble

Healthy donors age and sex matched to the patients

Patients that started DMARD therapy after the Baseline collection

Rheumatoid Arthritis With DMARDs

RA patients naive to TNF blockers recruited before the first administration of a TNF-blocker

Rheumatoid Arthritis Baseline for TNF-blockers

RA patients recruited at least 6 months after the start of a TNF-blocker

Rheumatoid Arthritis With TNF-blockers

Ankylosing Spondylitis

Patients with Ankylosing spondylitis naive to TNF-blockers, before the first TNF-block administration

Ankylosing Spondylitis Baseline for TNF Blocker

Ankylosing spondylitis recruited after a minimum of 6 months after the start of a TNF-blocker.

Ankylosing Spondylitis With TNF-blockers

Controls

Total

Sex: Female, Male

DAS28 for RA. 28 joints included. tender and swollen joint count (TEN28, SWO28). Erythrocyte sedimentation rate (ESR) is measured. The patient makes a subjective assessment (SA) of disease activity.
DAS28 ≤ 3.2 Inactive > 3.2 but ≤ 5.1 Moderate > 5.1 Very active
ASDAS for AS. Combines five disease activity variables in one single score
ASDAS
≤ 3.1Inactive > 3.1 but ≤ 2.1 Moderate > 2.1 but ≤ 3.5 Moderate > 3.5 Very active

Disease activity

ESR (mm/hr)

CRP (mg/dl)

Symptoms duration (years)

Osteoclasts will be differentiated from untreated patients and patients under several TNF blockers.

Osteoclast Differentiation Ex-vivo

Total area resorbed by osteoclasts as percentage of total area analyzed

Osteoclast Activity Ex-vivo

Overall Study

João Eurico Fonseca

Healthy donors age and sex matched to the patients - Healthy donors were not under any therapy therefore they were not at risk and Adverse effects were not assessed.

rheumatic diseases/phosphatase

Quantification of GADD34 Expression in RA

Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis

Најкомплетната база на податоци за лековити билки поддржана од науката